<DOC>
	<DOCNO>NCT03093714</DOCNO>
	<brief_summary>This multicenter , randomize , placebo-controlled , dose-escalation study . Enrollment plan occur approximately 14 global site . Approximately 24 subject CF .</brief_summary>
	<brief_title>A Study Evaluate Safety , PK PD FDL169 Cystic Fibrosis Subjects</brief_title>
	<detailed_description>This multicenter , randomize double-blind , placebo-controlled dose-escalation parallel-arm , dose-ranging study . Enrollment plan occur approximately 14 global site . Approximately 24 subject CF homozygous F508del-CFTR mutation enrol two cohort .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female subject confirm diagnosis CF define sweat chloride value ≥60 mmol/L quantitative pilocarpine iontophoresis two CFcausing mutation , document subject 's medical record confirm screen . Age 18 date inform consent . Weight ≥40 kg . Homozygous F508delCFTR mutation . Genotyping confirm screen . Ability perform valid , reproducible spirometry test demonstration force expiratory volume 1 sec ( FEV1 ) &gt; 40 % predict normal age , sex height . Screening laboratory test clinically significant abnormality would interfere study assessment ( judged Investigator ) . Subjects sexually active must agree follow study 's contraception requirement . An acute upper low respiratory tract infection , pulmonary exacerbation , change therapy pulmonary disease within 4 week prior Day 1 . Major complication lung disease ( include massive hemoptysis , pneumothorax , pleural effusion ) within 8 week prior screen . Impaired renal function know portal hypertension . History prolong QT and/or QTcF ( Fridericia 's correction ) interval ( &gt; 450 msec ) QTcF &gt; 450 msec Screening . History solid organ hematological transplantation . History alcohol abuse drug addiction ( include cannabis , cocaine opiate ) past year , ( judged Investigator ) . Use ivacaftor lumacaftor , within 4 week Day 1 Any change ( initiation , change type drug , dose modification , schedule modification , interruption , discontinuation , reinitiation ) chronic treatment/prophylaxis regimen CF CFrelated condition within 4 week prior Day 1 . Ongoing immunosuppressive therapy ( include systemic corticosteroid ) . Hemoglobin &lt; 10 g/dL . Abnormal liver function , screen . Abnormal renal function screening . Ongoing participation another clinical study prior participation without appropriate washout ( minimum 10 half live 30 day , whichever long ) prior Screening visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>